Delcath Systems, INC 8-K filings

Delcath Systems, Inc. has successfully raised approximately $7 million through a private placement with accredited investors, including existing investors, executives, and board members.

Delcath Systems has appointed Martha S. Rook as its new Chief Operating Officer, effective March 18, 2024.

Delcath Systems has announced the retirement of its Chief Operating Officer, John Purpura, and the departure of board member Roger Stoll.

Delcath Systems has obtained a permanent J-code for its HEPZATO treatment from the Centers for Medicare & Medicaid Services, effective April 1, 2024, which is expected to streamline billing and improve patient access.